FDA Brief

Warning letters Devices

FDA warning letter to

Insung Medical Co. Ltd.

High riskIssued Sep 23, 2025Posted Sep 30, 2025Center for Devices and Radiological Health

FDA warns Insung Medical over unreported ANKOR Endobronchial Tube malfunction and inadequate MDR procedures.

What happened

FDA inspected the company’s Gangwon, Korea facility from April 28, 2025, through May 1, 2025. FDA found the company did not report a complaint that an ANKOR Endobronchial Tube’s carinal cuff failed to inflate during a pre-use check, even though the company learned of the event on May 9, 2022. FDA also found the company’s Medical Device Reporting (MDR) procedure—the written steps for identifying and reporting device problems—lacked required definitions and instructions for completing and submitting reports.

What FDA found

  1. The company did not report a complaint that an ANKOR Endobronchial Tube’s carinal cuff failed to inflate during a pre-use check within 30 calendar days after learning of it on May 9, 2022.

    21 CFR 803.50(a)(2); 21 CFR 803.12(a)
  2. The company’s written MDR procedure did not define key terms such as “become aware,” “malfunction,” “serious injury,” and “reasonably suggests,” which are needed to decide whether an event must be reported.

    21 CFR 803.17(a)(1); 21 CFR 803.3; 21 CFR 803.20(c)(1)
  3. The company’s MDR procedure did not explain how to complete the FDA 3500A form or how to ensure all known information is submitted for each event.

    21 CFR 803.17(a)(3)
  4. The company’s MDR procedure did not describe when to submit supplemental or follow-up reports or what those reports must contain.

    21 CFR 803.17(a)(3); 21 CFR 803.56

What FDA wants

FDA asks the company to reply in writing within 15 business days describing the specific steps taken to address the violations, how it will prevent recurrence, and documentation of corrections or corrective actions, including a timetable if actions will take longer.

Who should pay attention

  • makers of life-supporting airway devices
  • companies that buy or distribute endobronchial tubes
  • quality teams handling device complaints and MDR reporting

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  2. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  3. O.N. Diagnostics, LLC

    FDA says O.N. Diagnostics sold changed VirtuOst VFA software without required clearance and had quality and reporting failures.

    High risk
  4. Lion Street Medical, d/b/a Pensar Medical LLC

    FDA warns Pensar Medical over unreported wound-therapy injuries and missing device reporting procedures.

    High risk